|By PR Newswire||
|February 3, 2014 12:30 PM EST||
SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen is focused on developing two drug technology platforms: (i) ATMs as a safer and more effective alternative to taxane chemotherapy, and (ii) its proprietary platform of super-benzopyrans, a group of small molecules with high efficacy against the full breadth of cells within a tumor, including the cancer stem cells, which have been resistant to drugs and radiation up to this point.
Dr. Stehn will hold the position of Director, ATM Program, and will have full oversight over the progress of this technology into the clinic in 2015. Professor Gunning will join the Company's Scientific Advisory Panel for ATM Technology.
"I am extremely pleased to join Novogen at a crucial period in the company's development," said Dr. Stehn. "The work we have conducted thus far in understanding ATMs leads us to believe we may have discovered a new approach to cancer therapy that could potentially offer patients a safer and more effective alternative to traditional chemotherapy, but the commonly-used taxane drugs in particular. I look forward to transitioning my work in academic research to Novogen and joining a team that is dedicated to developing new cost-effective approaches to many of the most lethal forms of cancer."
Dr. Stehn and Professor Gunning made a significant breakthrough when they discovered that the microfilament components of the cytoskeleton of cancer cells are made up largely of a particular isoform of the protein tropomyosin known as Tm5NM1. Elimination of Tm5NM1 significantly impacted the growth and survival of the cancer cell without adversely effecting normal tissue.
The first generation of drug directed against this isoform resulted in a significant anti-tumor effect in animals with human tumor xenografts (melanoma, neuroblastoma), without the collateral toxicity seen with previous compounds targeting the actin microfilaments. Their work was featured on the cover of the August (2013) edition of the journal, Cancer Research.
"I've dedicated my life's work to researching the cytoskeleton and developing treatments for children afflicted with cancer. I'm excited to become a part of Novogen as the Company moves this promising technology into the clinic in neuroblastoma, the most prevalent solid tumor in children. It is a great bonus that these drugs are likely to be equally effective against adult cancers such melanoma, ovarian and prostate cancer," said Professor Gunning.
During 2014, Novogen expects to file up to four Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for its ATM technology, enabling the company to start clinical trials in 2015.
Prior to joining Novogen, Dr. Stehn was Drug Development Coordinator and group leader of the Anti-Tropomyosin Drug Development Group in Prof Gunning's Oncology Research Unit in the School of Medical Sciences at the University of New South Wales. She received her PhD from the Garvan Institute of Medical Research in 2000. She was awarded a prestigious National Health and Medical Research Council (NHMRC) CJ Martin Fellowship to support her postdoctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT).
Prof. Gunning has published more than 140 research papers, and his research focuses on diseases of childhood, primarily cancer and muscle damage. He completed his PhD at Monash University on gene expression in the nervous system, and then spent nine years at Stanford University working first on neuronal differentiation and then on the regulation of the genes responsible for specifying the structure of muscle. His research group discovered that tropomyosins are used to specify the spatial and temporal properties of the cell cytoskeleton in all cells of the body.
Graham Kelly, Ph.D., Novogen Executive Director and Chief Executive Officer, said, "We are privileged to have the two inventors of this drug technology join us, and provide a considerable boost to our goal of entering the clinic with a lead candidate compound in early 2015. Their intimate knowledge of the technology, combined with our drug development experience is a very strong combination that will help us in our goal of finding new and highly effective approaches to treat many of the world's most deadly cancers."
About Anti-Tropomyosin (ATM) Drugs
ATM drugs target the tropomyosin protein component of actin microfilaments. Microfilaments, along with microtubules, form the bulk of a cell's cytoskeleton, a largely invisible structure that allows the cell to communicate internally and with neighboring cells, to move, to adhere to other cells, and to divide. Drugs targeting the cytoskeleton (micro tubular component) have been among the most widely-used drugs in oncology for over 30 years and include taxes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). However, the range of tumor types sensitive to these drugs is limited and their action is not limited to cancer cells, with resulting dose-limiting toxicity involving the gut, bone marrow and nerves.
Novogen ATM drugs have been designed to target the Tm5NM1 isoform of tropomyosin specifically. To date, cell types such as melanoma and neuroblastoma that have a high degree of inherent insensitivity to anti-microtubular drugs (e.g. taxanes), have proved highly sensitive to ATM drugs.
About Novogen Limited
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website, www.novogen.com.
16-20 Edgeworth David Ave, Hornsby NSW 2077 AUSTRALIA
P.O. Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA
 Cancer Res 73, 5169-5182 (2013). Justine R. Stehn et al. A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells.
SOURCE Novogen Limited
Most organizations prioritize data security only after their data has already been compromised. Proactive prevention is important, but how can you accomplish that on a small budget? Learn how the cloud, combined with a defense and in-depth approach, creates efficiencies by transferring and assigning risk. Security requires a multi-defense approach, and an in-house team may only be able to cherry pick from the essential components. In his session at 19th Cloud Expo, Vlad Friedman, CEO/Founder o...
Jul. 26, 2016 04:30 AM EDT Reads: 1,866
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 04:15 AM EDT Reads: 1,224
CenturyLink has announced that application server solutions from GENBAND are now available as part of CenturyLink’s Networx contracts. The General Services Administration (GSA)’s Networx program includes the largest telecommunications contract vehicles ever awarded by the federal government. CenturyLink recently secured an extension through spring 2020 of its offerings available to federal government agencies via GSA’s Networx Universal and Enterprise contracts. GENBAND’s EXPERiUS™ Application...
Jul. 26, 2016 03:45 AM EDT Reads: 1,830
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Jul. 26, 2016 03:30 AM EDT Reads: 1,062
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 02:45 AM EDT Reads: 1,535
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
Jul. 26, 2016 02:00 AM EDT Reads: 1,325
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
Jul. 26, 2016 01:45 AM EDT Reads: 1,307
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Jul. 26, 2016 01:45 AM EDT Reads: 2,192
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, explained how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
Jul. 26, 2016 01:30 AM EDT Reads: 996
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 01:30 AM EDT Reads: 1,687
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 01:30 AM EDT Reads: 1,475
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Jul. 26, 2016 01:15 AM EDT Reads: 2,527
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Jul. 26, 2016 12:45 AM EDT Reads: 639
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Jul. 26, 2016 12:00 AM EDT Reads: 2,148
“delaPlex Software provides software outsourcing services. We have a hybrid model where we have onshore developers and project managers that we can place anywhere in the U.S. or in Europe,” explained Manish Sachdeva, CEO at delaPlex Software, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 26, 2016 12:00 AM EDT Reads: 1,544